Pfizer Inc announced on Tuesday that it is seeking US approval for its experimental antiviral Covid-19 tablet, which in a clinical trial reduced the risk of hospitalisation or death in adults at risk of severe disease by 89 percent.
Pfizer announced that it has finished submitting its application for emergency use authorization (EUA) of Paxlovid to the US Food and Drug Administration, which included results from the drugmaker’s clinical trial.
